Cargando…

Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis

BACKGROUND: A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Liu, Zhenhua, Shi, Hongtai, Wang, Chunbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603743/
https://www.ncbi.nlm.nih.gov/pubmed/33131491
http://dx.doi.org/10.1186/s12885-020-07559-w
_version_ 1783603991534370816
author Xu, Haiyan
Liu, Zhenhua
Shi, Hongtai
Wang, Chunbin
author_facet Xu, Haiyan
Liu, Zhenhua
Shi, Hongtai
Wang, Chunbin
author_sort Xu, Haiyan
collection PubMed
description BACKGROUND: A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression and prognosis of BC patients using meta-analysis. METHODS: Literatures from PubMed, Embase, and the Cochrane Library (last update by May 20, 2020) were retrieved to find studies assessing the prognostic role of VDR in BC. The hazard ratios (HRs) for patients’ survival were extracted for pooled analyses. Subgroup analysis, sensitivity analysis and meta-regression were performed to explore the sources of heterogeneity. RESULTS: Seven articles containing eight studies with 2503 patients were enrolled. The results from the pooled analyses showed that the VDR expression generally had no relationship with BC patients’ overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and progression-free survival (PFS) (P > 0.05). Because only the number of studies exploring the relationship between VDR expression and OS is greater than five and there is heterogeneity, we explored the sources of heterogeneity of these studies. Subgroup analyses showed that the VDR expression in the nucleus had no relationship with OS, but high total VDR expression in the nucleus and cytoplasm was related to a better OS (pooled HR = 0.41; 95% CI = 0.18–0.95; P = 0.038). In addition, in subgroup of studies using cut-off values other than ‘immunoreactive score (IRS)>5’ and ‘IRS > 25′, high VDR expression was associated with a better OS (pooled HR = 0.47; 95% CI = 0.30–0.74; P = 0.001). Sensitivity analysis showed that the result pattern was not obviously affected by any single study. Meta-regression showed that the source of heterogeneity was not country (P = 0.657), pathological type (P = 0.614), molecular type (P = 0.423), staining location (P = 0.481), or cut-off value (P = 0.509). CONCLUSIONS: The protein expression level of VDR in entire BC cells evaluated by immunohistochemistry is related to the OS of BC patients. It is expected that a more individualized vitamin D intake and a more accurate prognosis assessment can be recommended for BC patients based on the VDR expression. Of course, more preclinical and clinical studies are needed.
format Online
Article
Text
id pubmed-7603743
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76037432020-11-02 Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis Xu, Haiyan Liu, Zhenhua Shi, Hongtai Wang, Chunbin BMC Cancer Research Article BACKGROUND: A higher vitamin D intake improves the prognosis of early stage breast cancer (BC) patients. We hypothesized that vitamin D intake should refer to vitamin D receptor (VDR) expression. In order to prove this hypothesis, we first intend to evaluate the correlation between VDR expression and prognosis of BC patients using meta-analysis. METHODS: Literatures from PubMed, Embase, and the Cochrane Library (last update by May 20, 2020) were retrieved to find studies assessing the prognostic role of VDR in BC. The hazard ratios (HRs) for patients’ survival were extracted for pooled analyses. Subgroup analysis, sensitivity analysis and meta-regression were performed to explore the sources of heterogeneity. RESULTS: Seven articles containing eight studies with 2503 patients were enrolled. The results from the pooled analyses showed that the VDR expression generally had no relationship with BC patients’ overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and progression-free survival (PFS) (P > 0.05). Because only the number of studies exploring the relationship between VDR expression and OS is greater than five and there is heterogeneity, we explored the sources of heterogeneity of these studies. Subgroup analyses showed that the VDR expression in the nucleus had no relationship with OS, but high total VDR expression in the nucleus and cytoplasm was related to a better OS (pooled HR = 0.41; 95% CI = 0.18–0.95; P = 0.038). In addition, in subgroup of studies using cut-off values other than ‘immunoreactive score (IRS)>5’ and ‘IRS > 25′, high VDR expression was associated with a better OS (pooled HR = 0.47; 95% CI = 0.30–0.74; P = 0.001). Sensitivity analysis showed that the result pattern was not obviously affected by any single study. Meta-regression showed that the source of heterogeneity was not country (P = 0.657), pathological type (P = 0.614), molecular type (P = 0.423), staining location (P = 0.481), or cut-off value (P = 0.509). CONCLUSIONS: The protein expression level of VDR in entire BC cells evaluated by immunohistochemistry is related to the OS of BC patients. It is expected that a more individualized vitamin D intake and a more accurate prognosis assessment can be recommended for BC patients based on the VDR expression. Of course, more preclinical and clinical studies are needed. BioMed Central 2020-11-01 /pmc/articles/PMC7603743/ /pubmed/33131491 http://dx.doi.org/10.1186/s12885-020-07559-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Xu, Haiyan
Liu, Zhenhua
Shi, Hongtai
Wang, Chunbin
Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title_full Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title_fullStr Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title_full_unstemmed Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title_short Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis
title_sort prognostic role of vitamin d receptor in breast cancer: a systematic review and meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603743/
https://www.ncbi.nlm.nih.gov/pubmed/33131491
http://dx.doi.org/10.1186/s12885-020-07559-w
work_keys_str_mv AT xuhaiyan prognosticroleofvitamindreceptorinbreastcancerasystematicreviewandmetaanalysis
AT liuzhenhua prognosticroleofvitamindreceptorinbreastcancerasystematicreviewandmetaanalysis
AT shihongtai prognosticroleofvitamindreceptorinbreastcancerasystematicreviewandmetaanalysis
AT wangchunbin prognosticroleofvitamindreceptorinbreastcancerasystematicreviewandmetaanalysis